To explore the potential active components and mechanism of Loki zupa(LKZP) for asthma treatment through pharmacodynamic evaluation，network pharmacology and molecular docking.Methods:The anti-asthmatic activity of LKZP was studied in ovalbumin(OVA)-induced asthma model mice.The chemical components of LKZP collected from literature and their targets were screened by Lipinsk's Rule of Five.After their intersection with the asthma targets，the anti-asthma targets of LKZP were determined.The core targets of LKZP for asthma treatment were determined by constructing a protein-protein interaction(PPI) network of therapeutic targets using the String.Then GO and KEGG enrichment analyses were proformed on the core targets by the DAVID.Finally，a component-target-pathway network was built by Cytoscape，and the binding energy of active components and targets was calculated by molecular docking.Results:A total of 136 potential active compounds and 841 targets of LKZP were screened，with 66 core targets.According to the network analysis，the key targets of LKZP for asthma treatment were MAPK1，EGFR，MAPK3，PIK3CA，AKT1，PIK3CB，PIK3CD，PIK3R1 and PRKCA.The signaling pathways were mainly related with the regulation of airway inflammation(such as PI3K-Akt signaling pathway，ErbB signaling pathway，and estrogen signaling) and the regulation of airway remodeling(such as HIF-1 signaling pathway，VEGF signaling pathway，and calcium signaling pathway).Finally，the molecular docking indicated a strong binding energy between key active components and targets.Conclusion:Sesquiterpenes，flavonoids and phenylpropanoids，the key active components in LKZP，regulate the airway inflammation and airway remodeling by multiple targets and pathways，thereby treating asthma.